Business Wire

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases ...
Newsweek

Target Recall Update: Customers Told ‘Immediately Stop’ Using Product

A recall has been issued for a gel insert for car seats and strollers that was sold at Target stores nationwide after a child received medical attention with second-degree burns to his back. The U.S ...
Benzinga.com

Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the ...

Ocular Therapeutix™, Inc. OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today ...
The Motley Fool

Here's Why Ocular Therapeutix Stock Is Sinking Today

The company's experimental dry-eye treatment produced some disappointing clinical trial results. Ocular Therapeutix's only revenue-generating product, Dextenza, isn't making ends meet yet. Investors ...